<DOC>
	<DOCNO>NCT00368459</DOCNO>
	<brief_summary>This multisite pilot randomize trial raloxifene placebo treatment woman Alzheimer 's disease .</brief_summary>
	<brief_title>Raloxifene Women With Alzheimer 's Disease</brief_title>
	<detailed_description>Raloxifene , selective estrogen receptor modulator , attract attention potential treatment Alzheimer 's disease woman , study disorder . To assess feasibility large-scale efficacy trial obtain initial estimate treatment effect , study investigator plan conduct pilot , randomize , double blind , placebo-controlled , clinical trial high-dose ( 120 mg daily ) raloxifene . Eligible participant postmenopausal woman late-onset Alzheimer 's disease mild-to-moderate severity take stable dose approve cholinesterase inhibitor . This pilot study design power detect significant , modest between-group difference magnitude provide current FDA-approved therapy . Study participant randomly allocate oral raloxifene identical placebo 12 month period . Outcomes interest obtain 6 12 month . The prespecified primary outcome change Alzheimer 's Disease Assessment Scale , cognitive subscale ( ADAS-cog ) , compare group 12 month . Prespecified secondary outcome include measure global severity ( Clinical Dementia Rating sum box ) , function ( Activities Daily Living ) , behavior ( Neuropsychiatric inventory ) , neuropsychological measure . Caregiver outcomes burden ( Zarit burden inventory ) distress ( Neuropsychiatric inventory ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>1 . Female 2 . Post menopausal 3 . Age least 60 year 4 . Eight year education history premorbid literacy 5 . By history , fluent speaker English 6 . Dementia ( DSMIVderived criterion ) present least six month begin age 60 old 7 . Mild moderate dementia , define MiniMental State examination ( MMSE ) score 12 26 , inclusive 8 . National Institute Neurological Communicative Disease Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criteria probable Alzheimer 's disease ( AD ) base result neurologist 's evaluation laboratory test 9 . Neurological history examination within normal limit age , except change consistent AD age 10 . Modified Ischemia Scale score 4 less 11 . Good physical health establish medical history , physical exam , baseline laboratory test 12 . Blood pressure &lt; 180/100 time entry 13 . No history , examination evidence , current insulindependent diabetes , stroke think impair cognition ( e.g. , cortical thalamic infarct ) , focal brain lesion neurological disorder likely affect cognition , serious medical illness likely limit participant 's ability complete study protocol 14 . No history pulmonary embolism , deep vein thrombosis , retinal vein occlusion 15 . No Diagnostic Statistical Manual ( DSM ) IV criterion Major Depressive Episode Axis I psychiatric disorder , AD , within past year 16 . Effective dose FDAapproved cholinesterase inhibitor least 6 month prior randomization ( usually donepezil 5 10 mg/d , rivastigmine 6 12 mg/d , galantamine 16 24 mg/d ) ; stable effective dose least 2 month prior randomization 17 . No psychotropic medication within 4 week study entry stable dose ( least 4 week month ) psychotropic medication 18 . No experimental mediation treatment cognitive impairment associate dementia within 2 month study entry 19 . No raloxifene within 6 month study entry 20 . No systemic estrogen , progestin , testosterone , relate gonadal hormone therapy within 2 month study entry 21 . No known contraindication raloxifene donepezil 22 . A primary caregiver know participant well able accompany regular assessment course study 23 . Assent consent participant plus informed consent participant 's next kin legally authorize representative 1 . Failure meet inclusion criterion</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>raloxifene , woman</keyword>
</DOC>